Windsor symphony director who traveled for stem cell transplant lauds new Windsor hospital program
Maestro Robert Franz experienced a recurrence in February, around five months before the hospital announced the launch of its autologuous stem cell transplant program.
"It's not easy as a sick person when you're not feeling good, and you're in the middle of chemo to be traveling back and forth two hours," Franz said.
"Some people have to go to Hamilton, which is, of course, twice as far."
Franz had to make the trip three or four times, he said.
Autologous, or auto stem cell transplants, involve a patient's own stem cells being collected and then reinfused back into their body following intensive chemotherapy or radiation, the hospital said in a news release Monday when it announced the program.
"This is a major step forward in offering comprehensive transplant services right here in Windsor-Essex," the release said.
Windsor hospital aiming to do 30 transplants per year
"Prior to this, patients had to travel significant distances to access specialized centres outside the region, resulting in logistical challenges, increased stress for patients and families and potential disruptions to continuity of care."
The hospital's initial roll-out of the program will focus on patients with multiple myeloma, it said.
Its goal is to provide transplants to 30 patients per year, and the first procedure was scheduled to take place July 8.
Franz was first diagnosed with Stage 4 non-Hodgkin lymphoma in 2021.
LISTEN | Robert Franz on his battle with cancer
He underwent intensive chemotherapy, and doctors told him if the cancer stayed away for three years, it likely wouldn't return.
But in February, he want to his doctor with a suspected gall bladder issue and learned that the cancer was back.
"The good news was it came back very localized," he said, "not throughout my body like it was the first time."
The treatment for a recurrence involves more chemotherapy and a stem cell transplant, he added.
"It's just incredible the things that they can do," he said.
Franz is still awaiting a PET scan to see if the process eradicated all the cancer.
"That's the hope and that's the desire," he said, "and ... we're going to wait and see."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Reproductive health benefits start-up Fertifa swoops on rival Juniper
A reproductive health start-up run by one of Britain's most prominent venture capitalists has swooped on one of its peers amid growing demand from large companies for the provision of fertility and other sexual health-related benefits to their workforces. Sky News understands that Fertifa, which is run by Eileen Burbidge, one of Britain's most prominent venture capitalists, has agreed a deal to buy Juniper, a two year-old London-based company which provides reproductive health insurance. Sources said the deal - worth an undisclosed sum - would be announced publicly on Thursday. Money latest: It will provide fresh evidence of the accelerating consolidation of an area of healthcare which has gained increasing prominence as part of companies' employee benefits packages in recent years. Fertifa counts Meta - the owner of Facebook, Instagram and WhatsApp - among its clients, along with other blue-chip businesses such as the private equity firm Hg Capital, H&M, Lululemon, MoFo, Space NK and Virgin Group. The start-up raised £5m in funding from investors including Notion Capital, Triple Point Ventures and Speedinvest two years ago, following an initial pre-seed round led by Passion Capital. Fertifa is the exclusive provider of the insurer Aviva UK's family planning and fertility benefit for many of its healthcare schemes. The start-up's offering is based on a per-employee, per-month pricing model, and offers reimbursement administration by charging a 5% fee on transaction volumes. It has also broadened its services in recent years by adding men's health, neurodiversity support and a payment plan allowing employees to avoid up-front costs. Juniper, which was founded by Ambra Zhang and Max Bacon, was set up to address a gap in the private medical insurance (PMI) market by focusing on reproductive health coverage. It also raised funding from external investors, including Insuretech Gateway and 2100. The rapid growth of private fertility service providers has given rise to greater scrutiny of their practices, with the collapse of Apricity, one prominent company in the sector, at the end of last year leaving some IVF patients thousands of pounds out of pocket and asking questions about the unregulated nature of the industry. At the time, a statement from the Human Fertilisation and Embryology Authority (HFEA) said it could "only regulate UK licensed fertility clinics, which are the premises where treatments take place". "The decision to cease trading was taken by Apricity's board," it added. "The HFEA is unable to help patients obtain a refund nor compensation. "Patients can also contact the licenced clinic where any procedures, such as egg collection, were due to take place. "We would expect Apricity to ensure that any eggs, sperm or embryos stored in the UK are looked after." Read more from Sky News: One market source said that Fertifa's acquisition of Juniper would strengthen its position as an emerging leader in the sector. Other corporate deals in the industry have included Nasdaq-listed Progyny's purchase of Apryl, a Verlin-based fertility benefits platform, in June 2024. Ms Burbidge and Juniper declined to comment on the deal on Wednesday ahead of a formal announcement.
Yahoo
2 hours ago
- Yahoo
Many US employers plan to pare health benefits as weight-loss spending soars
By Amina Niasse NEW YORK (Reuters) -More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey released by consulting firm Mercer on Wednesday. Among employers with 500 or more workers, 51% said they planned to increase cost-sharing in 2026, including raising deductibles and maximum out-of-pocket costs for workers. That is up from 45% of large employers who said they would increase cost-sharing for 2025. Concern over the cost of GLP-1 weight-loss drugs like Novo Nordisk's Wegovy has surged, with 77% of employers naming them a top issue, the consultancy said. "More clients are saying ... 'I don't know how much longer we can sustain covering these medications'," said Alysha Fluno, a pharmacy innovation leader at Mercer, in an interview. While some employers have covered GLP-1s hoping for long-term health savings, rising prices are forcing a rethink: "Some employers facing big cost increases in 2026 may feel this coverage is out of reach," Fluno said. Greater competition in the weight-loss drug market in coming years will give pharmacy benefit managers more negotiating power with drugmakers and drive meaningful cost reductions, said Fluno. Novo's Wegovy and Eli Lilly's Zepbound are listed at $1086 and $1059, respectively, but many patients pay less through their health plans. Prescription drug costs jumped 8% last year, according to the survey. Mercer has forecast a 5.8% rise in overall health benefit costs for 2025. Employers are also eyeing alternatives to traditional pharmacy benefit managers (PBMs), according to Mercer. PBMs such as CVS Caremark, Cigna's Express Scripts and UnitedHealthcare's Optum Rx act as middlemen between drug companies and consumers. They negotiate volume discounts and fees with drug manufacturers on behalf of employers and health plans, create lists of medications that are covered by insurance, and reimburse pharmacies for prescriptions. Drugmakers say they take an undisclosed cut of the discounts they receive rather than sharing them with patients and payers. Regulatory scrutiny and calls for transparency are fueling interest in new models and emerging PBMs, with 34% of employers considering a switch. The survey found 40% of employers are considering alternative contracting models for their prescription medicine benefits, such as those that price drugs based on the wholesale price that retail pharmacies pay for them. Regulators have criticized the three largest pharmacy benefit managers for steering patients toward more expensive drugs and inflating prices to generate revenue gains, an accusation that the industry denies. California pension fund CalPERS, the second-largest public purchaser of health benefits in the U.S., announced on Tuesday that Caremark would replace UnitedHealth's Optum Rx as the fund's PBM in 2026. CalPERS said its five-year contract with Caremark requires the PBM to boost transparency and oversight.
Yahoo
2 hours ago
- Yahoo
Premier Medical Collaborates with Walgreens to Expand Access to Care Across Central Florida
ORLANDO, Fla., July 16, 2025--(BUSINESS WIRE)--Premier Medical, a leading primary and multispecialty care provider in Central Florida, today announces a new collaboration with Walgreens to increase access to high-quality healthcare in local communities. Beginning this summer, Premier Medical, which is a part of the value-driven healthcare company, NeueHealth, will begin operating clinics inside select Walgreens locations, starting with two sites opening in Davenport, Fla., and Orlando, Fla., in July 2025. These in-store clinics will offer a range of services – including primary care, chronic condition management, and dermatology – and will serve patients enrolled in Medicare, Medicare Advantage, commercial, and select Medicaid plans. "We are excited to collaborate with Walgreens to make personalized care more accessible for Central Florida residents," said Craig Esquenazi, Director of Operations for Premier Medical. "This collaboration reflects our commitment to improving the health and well-being of local communities and making the care experience more convenient." "We're bringing trusted, high-quality care directly into our stores — making it easier for patients to get the services they need, right in their neighborhood," said Young Chang, Regional Healthcare Director for Walgreens. Premier Medical is planning additional clinic openings with Walgreens later this year. To find a Premier Medical clinic near you, visit: About Premier Medical Premier Medical is a Central Florida-based medical group dedicated to delivering accessible, high-quality primary and specialty care to diverse communities. With more than 30 years of experience serving the region, Premier Medical has built trusted relationships with patients and families across generations. Premier Medical is proud to be payer agnostic — welcoming patients from Medicare, Medicare Advantage, commercial plans, and select Medicaid plans. As part of NeueHealth, a value-driven healthcare company, Premier Medical offers a comprehensive range of services, including preventive care, chronic disease management, urgent care, dermatology, and telehealth. Through a strong focus on whole-person health, cultural competence, and coordinated care, Premier Medical empowers individuals and families to lead healthier lives and thrive in their communities. About Walgreens Founded in 1901, Walgreens ( has a storied heritage of caring for communities for generations, and proudly serves nearly 9 million customers and patients each day across its approximately 8,500 stores throughout the U.S. and Puerto Rico, and leading omni-channel platforms. Walgreens has approximately 220,000 team members, including nearly 90,000 healthcare service providers, and is committed to being the first choice for retail pharmacy and health services, building trusted relationships that create healthier futures for customers, patients, team members and communities. Walgreens is the flagship U.S. brand of Walgreens Boots Alliance, Inc. (Nasdaq: WBA), an integrated healthcare, pharmacy and retail leader. Its retail locations are a critical point of access and convenience in thousands of communities, with Walgreens pharmacists playing a greater role as part of the healthcare system and patients' care teams than ever before. Walgreens Specialty Pharmacy provides critical care and pharmacy services to millions of patients with rare disease states and complex, chronic conditions. View source version on Contacts Media Contact: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
